← All trials
NCT05995782
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2023
- Primary completion
- Sep 30, 2024
- Completion date
- Dec 31, 2024
- First posted
- Aug 16, 2023
- Last posted
- Aug 16, 2023
- Enrollment
- 64
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- 1ST Biotherapeutics, Inc.Lead sponsor
- 1ST Biotherapeutics, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.